SRT-3025

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSRT-3025
Drug Alias NameSRT-3025
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNAD-dependent deacetylase sirtuin 1 stimulants
TargetsNAD-dependent deacetylase sirtuin 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSirtris Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A